Mild Psoriatic Arthritis: What to Do When NSAIDs and Local Glucocorticoid Injections Have Not Controlled Symptoms
In mild psoriatic arthritis, first-line management with NSAIDs and local glucocorticoid injections aims for musculoskeletal symptom relief within weeks. When that target is not met, a structured next-line approach is indicated — and the right step depends on the patient's specific disease profile and treatment eligibility.
Clinical Scenario
This protocol is for patients with mild psoriatic arthritis — defined as oligoarticular or entheseal disease without poor prognostic factors and with limited skin involvement — in whom biologic DMARDs (bDMARDs) and JAK inhibitors are not appropriate.
When This Step Is Triggered
The previous line — NSAIDs for musculoskeletal symptom relief, supported by local glucocorticoid injections as adjunctive therapy — aimed to relieve musculoskeletal signs and symptoms within 4 weeks. This protocol is the appropriate next step when that symptom-relief target is not achieved.
Next-Line Approach
When initial therapy has not delivered adequate symptom control, escalation to a conventional synthetic disease-modifying antirheumatic drug (csDMARD) is the recommended direction. The specific agent and the full structured regimen are detailed in the complete protocol.
Treatment Targets
At this stage the clinical goals are at least a 50% reduction in disease activity within 3 months, and achievement of remission or low disease activity by 6 months. Therapy is reassessed and adjusted on an ongoing basis against these targets.
References
DOI: 10.1136/ard-2024-225531
- 'Mild disease' is defined as oligoarticular or entheseal disease without poor prognostic factors and limited skin involvement.
- Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.
- Since the EULAR recommendations adhere to a treat-to-target (T2T) approach which implies a reduction of disease activity by at least 50% within 3 months and reaching the treatment target within 6 months, a csDMARD should not be continued if these therapeutic goals are not attained.